This product is a neutral compound of aspirin and acetaminophen bonded by an ester bond. It has antipyretic and analgesic effects, with fewer adverse reactions than aspirin, and is easily tolerated by patients. After oral administration, it is not hydrolyzed in the gastrointestinal tract, is absorbed in the intestine and quickly reaches an effective concentration in the blood, and is characterized by rarely causing gastrointestinal bleeding.

It is a non-steroidal anti-inflammatory, antipyretic and analgesic drug with antipyretic, analgesic and anti-inflammatory effects. Its mechanism of action is basically the same as that of aspirin and acetaminophen, mainly producing analgesic, anti-inflammatory and antipyretic effects by inhibiting the synthesis of prostaglandins. Its duration of action is longer than that of aspirin and acetaminophen.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. It has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus aureus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis.

It has a good antibacterial effect on human tuberculosis bacteria, and its bactericidal effect is strongest at pH 5-5.5. It is currently the best bactericidal drug for tuberculosis bacteria that grow slowly in phagocytes in an acidic environment. The antibacterial concentration in vivo is 12.5μg/ml, and 50μg/ml can kill tuberculosis bacteria. The concentration that inhibits tuberculosis bacteria inside cells is 10 times lower than that outside cells, and it has almost no antibacterial effect in neutral and alkaline environments. The mechanism of action may be related to pyrazinoic acid. After pyrazinamide penetrates into phagocytes and enters the tuberculosis bacteria, the amidase in the bacteria removes the amide group and converts it into pyrazinoic acid to exert an antibacterial effect. In addition, because pyrazinamide is similar to nicotinamide in chemical structure, it interferes with dehydrogenase by replacing nicotinamide, prevents dehydrogenation, hinders the use of oxygen by tuberculosis bacteria, affects the normal metabolism of bacteria, and causes death.

The antibacterial spectrum of this product is the same as that of lincomycin, and its antibacterial activity is 4 to 8 times stronger than that of lincomycin. It has high antibacterial activity against aerobic Gram-positive cocci, such as Staphylococcus (including penicillin-resistant and methicillin-sensitive strains), hemolytic streptococci, grass-green streptococci, and Streptococcus pneumoniae. It also has good antibacterial effects on anaerobic bacteria. Most of the genera, such as Bacteroides, Fusobacterium, Actinomyces, Peptococcus, and Peptostreptococci are sensitive to this product. This product acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.